Long term experience of gamma knife radiosurgery for benign skull base meningiomas

W Kreil, J Luggin, I Fuchs, V Weigl, S Eustacchio, G Papaefthymiou

J Neurol Neurosurg Psychiatry 2005;76:1425–1430. doi: 10.1136/jnnp.2004.049213

See end of article for authors' affiliations

Correspondence to:
Dr W Kreil, Department of
Neurosurgery, Medical
University Graz,
Auenbruggerplatz 29,
A-8036 Graz, Austria;
wolfgang.kreil@meduni-
graz.at

Received 5 July 2004
In revised form
12 December 2004
Accepted 8 February 2005

Objectives: As most reports on the gamma knife have related only to short or mid-term results, we decided to evaluate the effectiveness and toxicity of radiosurgical treatment for benign skull base meningiomas in 200 patients with a follow up of 5–12 years to define the role of gamma knife radiosurgery (GKRS) for basal meningiomas and to provide further data for comparison with other treatment options.

Methods: In total, 99 patients were treated with a combination of microsurgical resection and GKRS. In 101 patients, GKRS was performed as the sole treatment option. Tumour volumes ranged from 0.38 to 89.8 cm³ (median 6.5 cm³), and doses of 7–25 Gy (median 12 Gy) were given to the tumour borders at covering isodose volume curves (range 20–80%, median 45%).

Results: The actuarial progression free survival rate was 98.5% at 5 years and 97.2% at 10 years. Passing radiation induced oedema occurred in two patients (1%). The neurological status improved in 83 cases (41.5%), remained unaltered in 108 (54%), and deteriorated in 9 (4.5%). Worsening was transient in seven patients (3.5%) and unrelated to tumour or treatment in one (0.5%). Repeated microsurgical resection was performed in five patients following GKRS (2.5%).

Conclusions: GKRS has proved to be an effective alternative to microsurgical resection, radiotherapy, and Linac based radiosurgery for adjunctive and primary treatment of selected patients with basal meningiomas. Because of the excellent long term tumour control rate and low morbidity associated with GKRS, this treatment option should be used more frequently in the therapeutic management of benign skull base meningiomas.

Advances in diagnostic and interventional radiology, improved microsurgical techniques, interdisciplinary skull base teamwork, and developments in anaesthesia and postoperative intensive care have expanded the scope and safety of the surgical treatment of basal meningiomas.¹ However, microsurgical resection of these tumours is frequently associated with considerable aggravation or new onset of neurological impairment,^{1–12} and meningioma recurrences are observed even when complete removal has been accomplished.^{1 3–6 9 12 13} Therefore, surgery alone cannot be the ideal solution to treat all skull base meningiomas, and less invasive therapeutic options have to be considered not only as adjunctive but as alternative primary treatment.^{2 6 10 14–20}

The promising results following gamma knife radiosurgery (GKRS) for skull base meningiomas in earlier reports^{17 18 20–25} have to be interpreted with caution because most centres have related their early experience to short or mid term observation periods. The purpose of this clinical study was to analyse retrospectively the toxicity and effectiveness of radiosurgical treatment in our patients with basal meningiomas with a follow up of 5–12 years to allow comparison with the risk–benefit ratio of other therapeutic methods.

PATIENTS AND METHODS

From April 1992 to June 1999, 237 patients with benign skull base meningiomas were treated with GKRS at our department. Five patients died of causes unrelated to GKRS or basal meningioma before the observation time reached 5 years, and 32 patients were lost to follow up. The remaining 200 patients were included in this study. None had received external beam radiotherapy in the past. The median age of the 40 men and 160 women was 57 years (range 10–81). The locations of the skull base meningiomas are listed in table 1.

Table 1 Distribution of tumour location in 200 patients with skull base meningiomas

Location	No. of tumours
Cavernous sinus	69
Petroclival	44
Sphenoid wing	32
Cerebellopontine angle	21
Frontobasis	13
Orbita	10
Craniocervical	7
Sella	4
Total	200

In total, 99 patients, who had undergone between one and four microsurgical resections, received additional GKRS 0.2–195.1 months after their last craniotomy (median 3.1 months) to prevent a progressive growth of recurrent or residual basal meningiomas. All of these tumours were specified as grade 1 meningiomas according to the World Health Organization tumour classification.²⁶ In total, 101 patients with typical findings on computerised tomography (CT) and/or magnetic resonance imaging (MRI) received GKRS as primary therapy because of medical infirmity, advanced age, or refusal of open surgery. None of the patients with primary GKRS suffered from increasing neurological deficit, especially progressive vision loss due to chiasmatic or optic nerve compression, as this is a clear indication for

Abbreviations: CND, cranial nerve deficit; CT, computed tomography; GKRS, gamma knife radiosurgery; MRI, magnetic resonance imaging; PIV, prescription isodose volume

Table 2 Distribution of pre- and postradiosurgical CNDs and neurological disorders in 200 patients with skull base meningiomas

Cranial nerve deficit (CND)/clinical symptom	No. of patients			
	Before GKRS	After GKRS		
		Improved	Stable	Deteriorated
Hyp/anosmia	5	–	5	–
Visual field defect	63	18	43	2 (1 transient)
Oculomotor nerve palsy	39	21	17	1 (transient)
Trochlear nerve palsy	9	3	6	–
Trigeminal sensory loss	18	8	10	–
Trigeminal neuralgia	23	16	7	2* (transient)
Abducent nerve palsy	23	12	11	–
Facial nerve palsy	13	6	7	–
Hearing loss	20	1	19	–
Tinnitus	7	–	7	–
Deglutition difficulty	6	–	6	–
Accessory nerve palsy	3	–	3	–
Tongue weakness	4	1	3	–
Hemiparesis	11	5	6	2 (1* unrelated, 1 transient)
Ataxia	9	5	4	–
Vertigo	25	8	17	–
Cephalaea	28	15	12	1 (transient)
Seizure activity	7	2	4	1 (transient)
Exophthalmos	15	8	7	–

*Appearance of new deficit following GKRS.

surgical resection of skull base meningiomas. The distribution of presenting clinical symptoms and signs at the time of GKRS is summarised in table 2.

A Leksell gamma knife model B was used for radiosurgical treatment. Except for a 10 year old patient who was treated under general anaesthesia (fig 1), the fitting of the stereotactic frame was performed under local anaesthesia. Tumour localisation was based on high resolution contrast enhanced CT or gadolinium enhanced MRI. Before and after GKRS, calibre measurements were made in three separate dimensions and tumour progression or involution was defined as a change of ± 2 mm. Volumetry was calculated at the time of GKRS but was not available for all cases in the follow up because several imaging studies were conducted by peripheral radiologists. Tumour volumes varied between 0.38 and 89.9 cm³ (median 6.5). Owing to large tumour volumes (19–89.8 cm³), we performed two stage radiosurgical treatment in seven patients and three stage GKRS in another to avoid adverse radiation related tissue effects.

Except for one patient who, for personal reasons, underwent the third radiosurgical partial volume treatment after 83.8 months, the intervals between gamma knife procedures ranged from 4.6 to 6.2 months (median 6). Treatment planning was performed using the Kula or GammaPlan software. Dose selection, guided by dose–volume analysis of prior radiosurgical series^{19–29} and our previous experience,^{15–17, 18, 30–32} were tailored to each case on the basis of tumour volume, specific location, and the projected radiobiological risk of adjacent neural structures. Apart from three patients who were treated very early in this series with marginal doses of 7, 8, and 25 Gy respectively, doses of 10–20 Gy (median 12) were delivered to the tumour borders, while the centres of the meningiomas received 15–56.7 Gy (median 26.7). Between 1 and 21 isocentres (median 6) were required to treat the mostly irregularly shaped meningiomas. The low doses were applied because of large tumour volume, and situation in the posterior fossa, to avoid radiation damage of the brain stem and cranial nerves. We retrospectively evaluated the conformity index according to the scoring ratio proposed by Paddick,³³ which measures how

well the created radiation field conforms to the size and shape of the target and attests that an undertreatment is as bad as an overtreatment. The theoretically perfect score of 1.00 lowers the smaller conformity the plan offers. Since October 2000, we have routinely applied the conformity index:

$$\text{Conformity Index} = \frac{\text{TV}_{\text{PIV}}}{\text{TV}} \times \frac{\text{TV}_{\text{PIV}}}{\text{PIV}} = \frac{\text{TV}_{\text{PIV}}^2}{\text{TV} \times \text{PIV}}$$

where TV = target volume, PIV = prescription isodose volume, and TVPIV = prescription target volume.

All patients were discharged within 24 hours following GKRS and were able to resume their preradiosurgical functional level within 3 to 5 days. Postradiosurgical imaging and clinical controls were conducted after 6 months, 12 months, and then once a year for the first 5 years, and if the tumour showed no growth, follow up was performed biennially thereafter. Tumour progression was defined as radiologically proven enlargement or need for additional surgical resection because of neurological deterioration despite an unchanged tumour volume. Rates of total tumour control were generated, and actuarial tumour control rates were calculated by the Kaplan-Meier method.³⁴

RESULTS

Radiological changes

During the observation period of 5–12 years (median 7.9), the tumour volume remained stable in 83 patients (41.5%) and decreased in 113 (56.5%). Tumour enlargement was observed in four patients (2%), 17, 25, 74, and 77 months, respectively, after combined surgical and radiosurgical treatment. In 39 patients (19.5%), reduced central contrast enhancement indicating marked tumour necrosis was demonstrated in the follow up studies. Temporarily increased peritumoural oedema, detected 3.6 and 6 months following secondary GKRS in two patients (1%) with extensive meningiomas mostly located in the region of the cavernous sinus completely subsided after oral administration of dexamethasone.

Clinical outcome

The neurological examinations revealed stable clinical status in 108 patients (54%) and improved neurological disorders in 83 cases (41.5%). Of the patients with clinical amelioration, 21 (10.5%) showed complete relief of neurological impairment, while transient (seven patients) or permanent (two cases) clinical deterioration was found in nine cases (4.5%)

Figure 1 (A) T1 weighted, gadolinium enhanced, cranial MRI (coronal view) at the time of radiosurgery showing the size of residual left sided parasellar meningioma in a 10 year old patient 0.3 months after partial resection. The tumour volume of 3.9 cm³ received 20 Gy at the covering 40% isodose line. (B) Latest follow up scan conducted 128 months after GKRS demonstrating the reduced meningioma size.

However, the permanent clinical worsening (new ipsilateral hemiparesis at 24 months following primary GKRS of a cavernous sinus meningioma) was not related to GKRS or tumour, but caused by stroke in a 68 year old patient. The distribution of preradiosurgical and postradiosurgical cranial nerve deficits and neurological disorders are listed in table 2.

Salvage surgical procedures

Five patients required repeated microsurgical resection after GKRS. In three patients, further debulking of the meningioma was necessary due to radiologically proven enlargement combined with neurological deterioration. Postoperatively, the impaired vision and oculomotor nerve dysfunction returned to normal in two patients respectively and the temporarily worsened hemiparesis in the third patient improved. Another patient with unaltered excellent clinical status underwent a second (conventional) surgery because the follow up scans displayed tumour progression. The remaining patient, harbouring a partially resected cavernous sinus meningioma with neuroradiologically unchanged extension, experienced progressive deterioration of a pre-existing visual field defect 5.5 months after radiosurgical treatment. The patient underwent microsurgical reoperation with further decompression of the optic chiasm and the optic nerve, but vision did not return to the same level as prior to GKRS.

Complications following GKRS

Five patients developed treatment related complications following GKRS, accounting for a complication rate of 2.5% (2% transient and 0.5% permanent complications). Increased seizure activity and aggravation of headache subsided completely in the two patients with temporarily increased peritumoural oedema. Two patients complained of new appearance of trigeminal neuralgia 12 and 16 months after secondary GKRS, respectively. No evidence of tumour progression was found on the imaging controls, and during the course of the following months, the trigeminal neuralgia resolved in both patients. The permanent visual deterioration in the patient with unchanged tumour volume that did not resolve after repeated microsurgery was considered as radiosurgically induced damage of the optic apparatus.

Impact of conformity index on tumour control and complications

We found 50 patients to have values below 0.7, 107 with scores between 0.7 and 0.9, 35 between 0.9 and 0.95, and 9 >0.95. Of the four patients with tumour progression after GKRS, only one patient with a conformity index of 0.62 and treatment involvement of 85% of the meningioma had obviously received suboptimal treatment. In the remaining three patients, with scores of 0.83, 0.85, and 0.89, progressive tumour growth was not caused by inadequate conformity.

The low index of 0.66 in our patient with permanent visual disturbance but radiologically stable tumour volume was caused by the attempt to shift the radiation dose away from the optic apparatus. The good conformity indices of 0.79 and 0.8 with the tumours totally covered by the prescription isodose volume do not explain the development of temporarily increased peritumoural oedema in two patients. The scores of 0.46 and 0.68 indicate undertreatment, but do not explain the occurrence of transient trigeminal neuralgia in two patients, as the radiosensitive structures of the cavernous sinus and the posterior fossa were deliberately excluded from radiosurgical treatment.

Actuarial control rates

Two patients with radiologically decreased tumour volume and improved neurological status died at 96 and 71 months

Figure 2 Kaplan-Meier³⁴ curve showing progression free survival rates after gamma knife radiosurgery (GKRS) of benign skull base meningiomas in 200 patients.

following GKRS, due to unrelated intercurrent disease (lymphoblastic cancer and pneumonia), aged 72 and 82 years, respectively. Applying Kaplan-Meier method,³⁴ progression free survival rate was 98.5% at 5 years' and 97.2% at 10 years' follow-up (fig 2).

DISCUSSION

The aim of microsurgery, which is considered the treatment of choice for skull base meningiomas, is complete excision with minimal morbidity and mortality.^{1 4 6 13 19 35 36} In more recent series, total removal of basal meningiomas was achieved in 60–87.5% of the patients. Between 30% and 56% of the patients suffered postoperative complications,^{3 4 9 37} but many authors mentioned only the percentage for specific complications and did not detail the absolute complication rate.^{2 5–8 10–12} The most common surgical sequelae were new or deteriorated pre-existing cranial nerve deficit (CND), occurring temporarily in 20–44% and permanently in 16–56% of the patients. The postoperative mortality rate ranges from 0% to 9% (median 3.6%).^{1–12 38} The variation of total recurrence rates among the surgical series (from 0% to 17%, median 6.7%) is seemingly caused by the range of the follow up periods.^{1–12} Furthermore, the recurrence/progression rates increase with the duration of follow up, and also seem to be influenced by tumour site and specific histopathological factors.^{3 6 13 35 39} Application of more sophisticated analysis, eventually including life table or Kaplan-Meier³⁴ studies, proved that the long term recurrence rates of microsurgically treated meningiomas are often underestimated. The risk of meningioma recurrence following total removal ranges from 3.5% to 19% at 5 years, whereas the 5 year progression rate of partially resected meningiomas varies between 25% and 60%.^{5 13 35 38 39} At 10 years, recurrence free rates range from 10% to 33% following radical resection, while tumour progression counts for 55–75% after partial meningioma removal.^{13 35 39}

As microsurgery alone still leaves us with a substantial recurrence or residual rate, considerable morbidity, and occasional mortality, less invasive alternative strategies have to be considered for the therapeutic management of basal meningiomas.^{2 4 6 10 14 16–20 24 29} In elderly or medically infirm patients particularly, it must be considered whether the meningioma will be likely to cause serious problems in the natural course of the remaining years and if the risks of surgery will exceed the potential benefits offered.

Conventional radiation therapy for the management of recurrent, partially removed, or unresectable benign meningiomas seems to prevent or delay progressive tumour growth with local control rates of 76–92% at 5 years and 77–82% at

Table 3 Summary of Linac based radiosurgical series for meningioma treatment

Author	No. of patients	Follow up, range (median)	Tumour volume (cm ³), range (median)	Marginal dose (Gy), range (median)	Tumour control rate (%)	Comp (%)
Engenhart ⁴³	17	1 to 60 (40)	N/A	N/A	94	53
Chang ⁴⁵	55	17 to 81 (48.8)	0.45 to 27.65 (7.33)	12 to 25 (18.3)	98	24
Villavicencio ⁴⁴	56	6 to 66 (26)	N/A	12 to 18.5 (15)	95	9

N/A, data not available in the publication. Comp, complications.

10 years.^{13 36 40–42} Complications following irradiation developed in 3.6–19% of the cases.^{36 40–42} One series reported that 9.4% of the patients with benign meningiomas died due to uncontrolled tumour growth following radiotherapy.⁴²

Comparisons, especially with Linac accelerator based series, are of interest (table 3), but it is difficult to compare among series with missing variables (such as tumour volume and marginal dose).^{43 44}

Clinically, 64.7–91% of the patients remained unchanged or experienced improvement of neurological disorders. Permanent or transient CNS were found in 3.6–22% of cases, parenchymal radiation necrosis developed in 3.6–11.8%, and radiation induced oedema in 3.6–23.5%.^{43–45} Engenhart *et al* observed treatment related mortality in one patient (5.9%) of their series.⁴³

Within the past few years, GKRS has begun to play an increasingly important role as a non-invasive alternative therapeutic modality for patients with skull base meningiomas.^{17 18 20 21 24 25} The aim of GKRS is to achieve long term tumour control with maintenance of the patient's clinical status and prevention of new treatment related morbidity.^{14 16 20 46} Excellent results were related in the early to interim gamma knife series (table 4), but the follow up intervals of these reports are too short to ensure that the biological behaviour of basal meningiomas has been altered.^{14 17 18 20–25} Only very limited data concerning the long term effectiveness in the use of GKRS for meningiomas are available.^{13 16 47} In our current series with 5–12 years' follow up, local control of skull base meningiomas could be obtained in 97.5%. The 5 year and 10 year progression free survival rates of 98.5% and 97.2%, respectively, compare favourably with the results of other treatment methods. Most of the patients (95.5%) had ameliorated or stable neurological status. Permanent clinical worsening was caused by unrelated intercurrent disease (stroke) in one patient. Transient deterioration in three patients with tumour progression was a

result of tumour compression and cannot be considered a radiation induced complication. The permanently deteriorated vision in one patient, the temporary appearance of a trigeminal neuralgia in two patients, and the passing worsening in two patients with presence of transient radiation induced oedema were the only treatment related complications following GKRS, accounting for a complication rate of 2.5% (2% transient and 0.5% permanent complications). Similar results were reported by Kondziolka *et al*¹⁶ and Kobayashi *et al*.⁴⁷ In all of the series, no death resulted from the radiosurgical treatment of basal meningiomas with GKRS. Only one early report⁴⁸ described neuroradiological changes in one of 50 patients (2%) that could be attributed to radionecrosis of brain parenchyma.

Concerning the role of GKRS for primary treatment, an open microsurgical approach is recommended to establish tissue diagnosis if the findings on preradiosurgical MRI/CT scans do not clearly display the typical radiological features of benign meningioma, so that the possibility of other lesions can be ruled out.²⁵

Comparison of the radiosurgical series of basal meningiomas shows a trend towards lower treatment doses over the years associated with unchanged excellent tumour control rates but reduced incidence of radiation induced adverse side effects.^{17 18 20–22 24 31 46 48 51 52} Currently, we advocate that benign meningiomas should be treated with margin doses of 12 Gy, but the radiosensitivity of juxtaposed cranial nerves or the brainstem sometimes necessitates an application of lower doses to the small portion of the meningioma borders directly in contact with the structures at risk. The anterior visual pathways seem to be less radio-resistant than the other cranial nerves. Although no clear threshold doses have been found for the optic nerve, chiasm, and tract^{30 50} we keep maximum irradiation exposure of these structures below 10 Gy. Nevertheless, one patient of our current series experienced permanent deterioration of vision without

Table 4 Summary of GKRS based series for meningioma treatment

Author	No. of patients	Follow up, range (median)	Tumour volume (cm ³), range (median)	Marginal dose (Gy), range (median)	Tumour control rate (%)	Comp (%)
Kondziolka ²⁹	50	6 to 34 (N/A)	N/A	10 to 25(16.7)	96	6
Duma ²¹	34	6 to 54 (26)	0.5 to 20.4 (5.17)	10 to 20 (16)	100	20
Ganz ⁴⁹	20	12 to 27 (N/A)	N/A	5.1 to 28.5 (N/A)	80	0
Nikolatos ⁴⁸	50	4 to 31 (14)	0.6 to 20 (8.6)	10 to 28 (18)	98	6
Liscak ²³	53	2 to 60 (19)	0.9 to 31.4 (7.8)	10 to 14 (12)	100	13
Iwai ²²	24	6 to 36 (17.1)	0.1 to 28.6 (11)	8 to 15 (10.6)	100	4
Morita ⁵⁰	88	12 to 83 (35)	N/A (10)	12 to 20 (16)	98	14.8
Nakaya ⁴⁶	11	21 to 57 (35.7)	1.6 to 28.9 (7.1)	9.9 to 10 (10)	100	9
Kondziolka ¹⁶	99	60 to 120 (N/A)	0.24 to 24 (4.7)	9 to 25 (16)	93	13
Aichholzer ¹⁴	46	36 to 76 (48)	N/A	9 to 25 (15.9)	97.5	4.3
Pendl ³²	164	25 to 97 (55)	0.5 to 89.9 (8.3)	7 to 25 (12)	98	1.8
Kobayashi ⁴⁷	54	60 to 108 (84)	N/A	N/A (14.5)	89	5.5 (?)
Eustacchio ¹⁵	121	60 to 117 (82)	0.5 to 89.9 (6.8)	7 to 25 (13)	98.3	3.3
Current study	200	60 to 144 (95)	0.38 to 89.9 (6.5)	7 to 25 (12)	97.5	2.5

N/A, data not available in the publication. Comp, complications.

tumour progression, although all parts of the optic pathways received less than 10 Gy. The encouraging preliminary results after fractionated stereotactic radiotherapy for lesions directly abutting the critical structures of the optic apparatus, combining the advantages of physical dose localisation of stereotactic radiosurgery with the radiobiological benefits of dose fractionation, require studies with longer follow up periods to determine the value of this therapeutic approach.⁵³ The nerves controlling the ocular muscles are presumed to tolerate doses even beyond 20 Gy,^{15 19 21 29 30} but in our patient, passing oculomotor nerve palsy developed, although no part of the third cranial nerve received more than 10–20 Gy. Consistent with our experience, Morita *et al* found one patient to have permanent new oculomotor palsy following application of 10 Gy to the cavernous sinus.⁵⁰

Prevailing reports stated that the fifth cranial nerve seems to tolerate doses of up to 20 Gy,^{15 17 19 30 50} but the new onset of transient trigeminal neuralgia following administration of 12–17 Gy to the trigeminal nerve was observed in two patients of our series.

Commonly, extensive intracranial lesions are considered not suitable for GKRS, because the radiobiological tolerance of the surrounding brain tissue for the currently prescribed single doses sets practical maximal volume limit to around 20 cm³.^{16 28 48 51 54} In fact, the passing peritumoural oedema, occurring in one patient very early in our study after a tumour volume of 23 cm³ had received an edge dose of 12 Gy at the 40% covering isodose line, seemingly resulted from inadequate dose–volume relation. Owing to this experience, we developed our proposed strategy of performing staged radiosurgical treatment for larger meningiomas to maximise potential benefits, which has been rarely described in adequate literature.^{17 18 22 23 31} As we obtained local tumour control and clinical amelioration in all cases following staged GKRS, we assume that this strategy may expand the indication for radiosurgical treatment in benign, slowly growing lesions with diameters larger than 3 cm.^{22 31} However, careful analysis of the treatment parameters (meningioma volume 7.4 cm³, margin dose 12 Gy at the 40% isodose curve) gave no explanation for the temporary appearance of radiation induced oedema in another patient.

The application of the aforementioned conformity index showed that tumour progression in one patient of our current series was due to undertreatment. Further data will be necessary to establish its final role in the treatment planning of GKRS.

Some authors have mentioned that surgical resection following GKRS becomes extremely difficult due to post-irradiation changes in the tumour, such as formation of adherent scar tissue or loss of defining arachnoidal planes of dissection.^{55 56} This is in contrast to our own experience in the two patients who underwent further, conventional surgery at our department after a combined surgical and radiosurgical treatment. During the operation, we found highly avascular tumour tissue, as we had expected, following endovascular occlusion of feeding vessels without any adherence to the juxtaposed neurovascular structures.

Aside from other considerations, appealing aspects of GKRS are the short duration of hospitalisation (less than 48 hours) and the quick return to normal daily life activities (3–5 days following GKRS) on the same level as prior to radiosurgery, thus favourably contributing to the cost effectiveness of this minimally invasive treatment method.^{21 29}

CONCLUSION

In our 5–12 year experience, GKRS provided an excellent long term tumour control rate associated with maintenance of neurological function and low treatment related morbidity

for selected patients with benign skull base meningiomas. The long term outcome following GKRS for skull base meningiomas treatment favourably compares with the results obtained by microsurgery, conventional radiotherapy, and Linac based radiosurgery either in combination or on its own. The apparently better results of GKRS in the treatment for skull base meningiomas should provide the impetus for even more aggressive application of this approach in the management of basal meningiomas.

Nevertheless, increasing neurological deficit, especially rapidly progressive vision loss due to chiasmatic or optic nerve compression, is a clear indication for surgical resection. With regard to the possibility of an additional radiosurgical approach to residual tumours and the excellent results, following combined microsurgical–radiosurgical treatment, the objective of surgical treatment of basal meningiomas should be preservation of function and of as much normal tissue as possible, rather than radical resection. Patients harbouring recurrences of skull base meningiomas should receive GKRS rather than undergo repeated open resection.

In patients with advanced age, significant concomitant medical problems, high risk tumour location or patients who are not willing to undergo an open microsurgical procedure, we would recommend performing GKRS as a safe and effective alternative primary treatment modality, with close and frequent clinical and neuroradiological follow up. However, the long natural history of skull base meningiomas necessitates observation periods of at least 10–20 years before any final conclusion regarding the various treatment options can be expected.

Authors' affiliations

W Kreil, J Luggin, I Fuchs, V Weigl, S Eustacchio, G Papaefthymiou, Department of Neurosurgery, Medical University, Graz, Austria

Competing interests: none declared

REFERENCES

- 1 Sekhar LN, Swamy NK, Jaiswal V, *et al*. Surgical excision of meningiomas involving the clivus: preoperative and intraoperative features as predictors of postoperative functional deterioration. *J Neurosurg* 1994;**81**:860–8.
- 2 Arnaudovic KI, Al Mefly O, Husain M. Ventral foramen magnum meningiomas. *J Neurosurg* 2000;**92**:71–80.
- 3 Bricolo AP, Turazzi S, Talacchi A, *et al*. Microsurgical removal of petroclival meningiomas: a report of 33 patients. *Neurosurgery* 1992;**31**:813–28.
- 4 Coldwell WT, Fukushima T, Giannotta SL, *et al*. Petroclival meningiomas: surgical experience in 109 cases. *J Neurosurg* 1996;**84**:20–8.
- 5 De Jesus O, Sekhar LN, Parikh HK, *et al*. Long-term follow-up of patients with meningiomas involving the cavernous sinus: recurrence, progression, and quality of life. *Neurosurgery* 1996;**39**:915–19.
- 6 DeMonte F, Smith HK, Al Mefly O. Outcome of aggressive removal of cavernous sinus meningiomas. *J Neurosurg* 1994;**81**:245–51.
- 7 George B, Lot G, Boissonnet H. Meningioma of the foramen magnum: a series of 40 cases. *Surg Neurol* 1997;**47**:371–9.
- 8 Samii M, Tatagiba M. Experience with 36 surgical cases of petroclival meningiomas. *Acta Neurochir (Wien)* 1992;**118**:27–32.
- 9 Samii M, Klekamp J, Carvalho G. Surgical results for meningiomas of the craniocervical junction. *Neurosurgery* 1996;**39**:1086–94.
- 10 Samii M, Carvalho GA, Tatagiba M, *et al*. Surgical management of meningiomas originating in Meckel's cave. *Neurosurgery* 1997;**41**:767–74.
- 11 Spallone A, Makhmudov UB, Mukhamedjanov DJ, *et al*. Petroclival meningioma. An attempt to define the role of skull base approaches in their surgical management. *Surg Neurol* 1999;**51**:412–19.
- 12 Thomas NW, King TT. Meningiomas of the cerebellopontine angle. A report of 41 cases. *Br J Neurosurg* 1996;**10**:59–68.
- 13 Mathiesen T, Lindquist C, Kihlstrom L, *et al*. Recurrence of cranial base meningiomas. *Neurosurgery* 1996;**39**:2–7.
- 14 Aichholzer M, Bertalanffy A, Dietrich W, *et al*. Gamma knife radiosurgery of skull base meningiomas. *Acta Neurochir (Wien)* 2000;**142**:647–52.
- 15 Eustacchio S, Trummer M, Fuchs I, *et al*. Preservation of cranial nerve function following Gamma Knife radiosurgery for benign skull base meningiomas: experience in 121 patients with follow-up of 5 to 9.8 years. *Acta Neurochir Suppl* 2002;**84**:71–6.
- 16 Kondziolka D, Levy EI, Niranjan A, *et al*. Long-term outcomes after meningioma radiosurgery: physician and patient perspectives. *J Neurosurg* 1999;**91**:44–50.
- 17 Pendt G, Schrotter O, Eustacchio S, *et al*. Stereotactic radiosurgery of skull base meningiomas. *Minim Invasive Neurosurg* 1997;**40**:87–90.

- 18 **Pendl G**, Schrottner O, Eustacchio S, et al. Cavernous sinus meningiomas—what is the strategy: upfront or adjuvant gamma knife surgery? *Stereotact Funct Neurosurg* 1998;**70**(suppl 1):33–40.
- 19 **Steiner L**, Lindquist Ch, Steiner M. Meningiomas and Gamma Knife radiosurgery. Al Mefty, O. New York, Raven Press, 1991:263–72.
- 20 **Subach BR**, Lunsford LD, Kondziolka D, et al. Management of petroclival meningiomas by stereotactic radiosurgery. *Neurosurgery* 1998;**42**:437–43.
- 21 **Duma CM**, Lunsford LD, Kondziolka D, et al. Stereotactic radiosurgery of cavernous sinus meningiomas as an addition or alternative to microsurgery. *Neurosurgery* 1993;**32**:699–704.
- 22 **Iwai Y**, Yamanaka K, Yasui T, et al. Gamma knife surgery for skull base meningiomas. The effectiveness of low-dose treatment. *Surg Neurol* 1999;**52**:40–4.
- 23 **Liscak R**, Simonova G, Vymazal J, et al. Gamma knife radiosurgery of meningiomas in the cavernous sinus region. *Acta Neurochir(Wien)* 1999;**141**:473–80.
- 24 **Muthukumar N**, Kondziolka D, Lunsford LD, et al. Stereotactic radiosurgery for anterior foramen magnum meningiomas. *Surg Neurol* 1999;**51**:268–73.
- 25 **Nakatomi H**, Sasaki T, Kawamoto S, et al. Primary cavernous sinus malignant lymphoma treated by gamma knife radiosurgery: case report and review of the literature. *Surg Neurol* 1996;**46**:272–8.
- 26 **Kleihues P**, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. *Brain Pathol* 1993;**3**:255–68.
- 27 **Flickinger JC**. An integrated logistic formula for prediction of complications from radiosurgery. *Int J Radiat Oncol Biol Phys* 1989;**17**:879–85.
- 28 **Flickinger JC**, Kondziolka D, Lunsford LD. Dose selection in stereotactic radiosurgery. *Neurosurg Clin N Am* 1999;**10**:271–80.
- 29 **Kondziolka D**, Lunsford LD, Coffey RJ, et al. Stereotactic radiosurgery of meningiomas. *J Neurosurg* 1991;**74**:552–9.
- 30 **Leber KA**, Bergloff J, Pendl G. Dose-response tolerance of the visual pathways and cranial nerves of the cavernous sinus to stereotactic radiosurgery. *J Neurosurg* 1998;**88**:43–50.
- 31 **Pendl G**, Unger F, Papaefthymiou G, et al. Staged radiosurgical treatment for large benign cerebral lesions. *J Neurosurg* 2000;**93**(suppl 3):107–12.
- 32 **Pendl G**, Eustacchio S, Unger F. Radiosurgery as alternative treatment for skull base meningiomas. *J Clin Neurosci* 2001;**8**(suppl 1):12–14.
- 33 **Paddick I**. A simple scoring ratio to index the conformity of radiosurgical treatment plans. Technical note. *J Neurosurg* 2000;**93**(suppl 3):219–22.
- 34 **Kaplan E**, Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc* 1958;**53**:457–81.
- 35 **Mirimanoff RO**, Dosoretz DE, Linggood RM, et al. Meningioma: analysis of recurrence and progression following neurosurgical resection. *J Neurosurg* 1985;**62**:18–24.
- 36 **Nutting C**, Brada M, Brazil L, et al. Radiotherapy in the treatment of benign meningioma of the skull base. *J Neurosurg* 1999;**90**:823–7.
- 37 **Cusimano MD**, Sekhar LN, Sen CN, et al. The results of surgery for benign tumors of the cavernous sinus. *Neurosurgery* 1995;**37**:1–9.
- 38 **Jung HW**, Yoo H, Paek SH, et al. Long-term outcome and growth rate of subtotally resected petroclival meningiomas: experience with 38 cases. *Neurosurgery* 2000;**46**:567–74.
- 39 **Ayerbe J**, Lobato RD, de la CJ, et al. Risk factors predicting recurrence in patients operated on for intracranial meningioma. A multivariate analysis. *Acta Neurochir (Wien)* 1999;**141**:921–32.
- 40 **Connell PP**, Macdonald RL, Mansur DB, et al. Tumor size predicts control of benign meningiomas treated with radiotherapy. *Neurosurgery* 1999;**44**:1194–9.
- 41 **Glahalm J**, Bloom HJ, Crow JH. The role of radiotherapy in the management of intracranial meningiomas: the Royal Marsden Hospital experience with 186 patients. *Int J Radiat Oncol Biol Phys* 1990;**18**:755–61.
- 42 **Goldsmith BJ**, Wara WM, Wilson CB, et al. Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. *J Neurosurg* 1994;**80**:195–201.
- 43 **Engenhart R**, Kimmig BN, Hover KH, et al. Stereotactic single high dose radiation therapy of benign intracranial meningiomas. *Int J Radiat Oncol Biol Phys* 1990;**19**:1021–6.
- 44 **Villavicencio AT**, Black PM, Shrieve DC, et al. Linac radiosurgery for skull base meningiomas. *Acta Neurochir(Wien)* 2001;**143**:1141–52.
- 45 **Chang SD**, Adler JR Jr. Treatment of cranial base meningiomas with linear accelerator radiosurgery. *Neurosurgery* 1997;**41**:1019–25.
- 46 **Nakaya K**, Hayashi M, Nakamura S, et al. Low-dose radiosurgery for meningiomas. *Stereotact Funct Neurosurg* 1999;**72**(suppl 1):67–72.
- 47 **Kobayashi T**, Kida Y, Mori Y. Long-term results of stereotactic gamma radiosurgery of meningiomas. *Surg Neurol* 2001;**55**:325–31.
- 48 **Nicolato A**, Ferraresi P, Forani R, et al. Gamma knife radiosurgery in skull base meningiomas. Preliminary experience with 50 cases. *Stereotact Funct Neurosurg* 1996;**66**(suppl 1):112–20.
- 49 **Ganz JC**, Backlund EO, Thorsen FA. The results of gamma knife surgery of meningiomas, related to size of tumor and dose. *Stereotact Funct Neurosurg* 1993;**61**(suppl 1):23–9.
- 50 **Morita A**, Coffey RJ, Foote RL, et al. Risk of injury to cranial nerves after gamma knife radiosurgery for skull base meningiomas: experience in 88 patients. *J Neurosurg* 1999;**90**:42–9.
- 51 **Ganz JC**, Schrottner O, Pendl G. Radiation-induced edema after gamma knife treatment for meningiomas. *Stereotact Funct Neurosurg* 1996;**66**(suppl 1):129–33.
- 52 **Pan DH**, Guo WY, Chang YC, et al. The effectiveness and factors related to treatment results of gamma knife radiosurgery for meningiomas. *Stereotact Funct Neurosurg* 1998;**70**(suppl 1):19–32.
- 53 **Selch MT**, Ahn E, Laskari A, et al. Stereotactic radiotherapy for treatment of cavernous sinus meningiomas. *Int J Radiat Oncol Biol Phys* 2004;**59**:101–11.
- 54 **Kang CS**, Zheng LG, Xu DS. Dose-volume effect in gamma knife radiosurgery of meningiomas. *Stereotact Funct Neurosurg* 1999;**73**:72–8.
- 55 **Dolenc V**. Comment to Liscak R, Simonova G, Vymazal J, Janouskova L and Vladyka V: Gamma knife radiosurgery of meningiomas in the cavernous sinus region. *Acta Neurochir(Wien)* 1999;**141**:480.
- 56 **Sekhar L**. Comment to Iwai Y, Yamanaka K, Yasui T, Komiyama M, Nishikawa M, Nakajima H and Kishi H: Gamma knife surgery for skull base meningiomas. The effectiveness of low-dose treatment. *Surg Neurol* 1999;**52**:44.